Researchers Announce ''Breakthrough Discovery'' In Type-2 Diabetes Using Illumina, Inc.'s HumanHap300 And Human-1 Genotyping BeadChips

SAN DIEGO--(BUSINESS WIRE)--Illumina (NASDAQ:ILMN) today announced that researchers using the Infinium® HumanHap300 and Human-1 BeadChips uncovered four important gene variations that increases the risk of developing type-2 diabetes, the most common form of the disease. These results were published in the journal, Nature, and are believed to explain up to 70 percent of the genetic background of type-2 diabetes.